Clinical Research Directory
Browse clinical research sites, groups, and studies.
Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery
Sponsor: Seoul National University Hospital
Summary
The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.
Official title: Comparative Analysis of Seroma and Hematoma Rates: MAXIGESIC vs. Ketorolac in Breast Cancer Surgery Patients
Key Details
Gender
FEMALE
Age Range
20 Years - 70 Years
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2025-05-01
Completion Date
2026-02-20
Last Updated
2024-09-19
Healthy Volunteers
No